Evidence map›Paper›PMID 28957426›Full record

ArticlePLoS pathogens2017

Vpma phase variation is important for survival and persistence of Mycoplasma agalactiae in the immunocompetent host.

Rohini Chopra-Dewasthaly, Joachim Spergser, Martina Zimmermann, Christine Citti, Wolfgang Jechlinger, Renate Rosengarten

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Vaccines · 2024
    Review
  3. Review
  4. Serum Resistance ofPathogens (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Frontiers in veterinary science · 2022
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Phase Variation ofMicrobiology spectrum · 2019
    Article
  14. Article
  15. Article
  16. Comparative Analysis ofFrontiers in genetics · 2018
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Rohini Chopra-DewasthalyInstitute of Bacteriology, Mycology and Hygiene, Department of Pathobiology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.ORCID http://orcid.org/0000-0002-6768-1256
Joachim SpergserInstitute of Bacteriology, Mycology and Hygiene, Department of Pathobiology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.ORCID http://orcid.org/0000-0002-0164-0179
Martina ZimmermannInstitute of Bacteriology, Mycology and Hygiene, Department of Pathobiology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.
Christine CittiUMR1225, INRA, ENVT, Ecole Nationale Vétérinaire, 23 Chemin des Capelles, Toulouse, France.
Wolfgang JechlingerInstitute of Bacteriology, Mycology and Hygiene, Department of Pathobiology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.
Renate RosengartenInstitute of Bacteriology, Mycology and Hygiene, Department of Pathobiology, University of Veterinary Medicine Vienna, Veterinärplatz 1, Vienna, Austria.ORCID http://orcid.org/0000-0002-7014-5438
University of Veterinary Medicine Vienna · ATÉcole Nationale Vétérinaire de Toulouse · FR

Funding

Austrian Science Fund FWF P 23595
6 · The paper itself

Abstract

Despite very small genomes, mycoplasmas retain large multigene families encoding variable antigens whose exact role in pathogenesis needs to be proven. To understand their in vivo significance, we used Mycoplasma agalactiae as a model exhibiting high-frequency variations of a family of immunodominant Vpma lipoproteins via Xer1-mediated site-specific recombinations. Phase-Locked Mutants (PLMs) expressing single stable Vpma products served as first breakthrough tools in mycoplasmology to study the role of such sophisticated antigenic variation systems. Comparing the general clinical features of sheep infected with a mixture of phase-invariable PLMs (PLMU and PLMY) and the wild type strain, it was earlier concluded that Vpma phase variation is not necessary for infection. Conversely, the current study demonstrates the in vivo indispensability of Vpma switching as inferred from the Vpma phenotypic and genotypic analyses of reisolates obtained during sheep infection and necropsy. PLMY and PLMU stably expressing VpmaY and VpmaU, respectively, for numerous in vitro generations, switched to new Vpma phenotypes inside the sheep. Molecular genetic analysis of selected 'switchover' clones confirmed xer1 disruption and revealed complex new rearrangements like chimeras, deletions and duplications in the vpma loci that were previously unknown in type strain PG2. Another novel finding is the differential infection potential of Vpma variants, as local infection sites demonstrated an almost complete dominance of PLMY over PLMU especially during early stages of both conjunctival and intramammary co-challenge infections, indicating a comparatively better in vivo fitness of VpmaY expressors. The data suggest that Vpma antigenic variation is imperative for survival and persistence inside the immunocompetent host, and although Xer1 is necessary for causing Vpma variation in vitro, it is not a virulence factor because alternative Xer1-independent mechanisms operate in vivo, likely under the selection pressure of the host-induced immune response. This singular study highlights exciting new aspects of mycoplasma antigenic variation systems, including the regulation of expression by host factors.

Indexed as

AnimalsAntigenic VariationBacterial ProteinsHost-Pathogen InteractionsLipoproteinsMembrane ProteinsMultigene FamilyMycoplasma agalactiaeMycoplasma InfectionsRecombination, GeneticSheepBacterial ProteinsLipoproteinsMembrane Proteins

Identifiers

PMID28957426
PMCPMC5634654
OpenAlexW2758830908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.